Toronto BNB Pilot Study

NCT02082587 | Completed

• 1 other identifier: OCREB 14-006
• Study Type: observational
• Target: 39
• Locations: 1 country
• Sites: 3

Brief Summary

As treatments improve and patients live longer with cancer, even after it has spread to the brain, efforts to improve quality of life are growing. Neurocognitive function (thinking ability and memory) is an area of particular concern for patients with brain metastases (cancer that can spread to the brain). Although there are established tests to measure neurocognitive function, these require a face-to-face assessment and can take a long time to complete. As a result, efforts to use these tests to measure changes in neurocognitive function in patients following treatment for brain metastases have resulted in a large proportion of patients who do not return for follow-up. This has limited the ability to evaluate the impact of current treatments on neurocognitive function. This study aims to evaluate a shorter, telephone-based neurocognitive assessment tool, which would make it easier for patients to complete these tests in follow-up. If this new tool is found to reliably measure neurocognitive function, it could be used for future studies evaluating new interventions that prevent or treat neurocognitive deterioration following treatment of brain metastases. This is the first prospective study to evaluate the feasibility and reliability of a novel telephone-based brief neurocognitive assessment battery (Toronto BNB) compared with the same battery delivered face-to-face in this population. The investigators hypothesize that telephone administration of this brief neurocognitive battery will reliably evaluate neurocognitive function and improve patient ability to complete follow-up assessments.

Conditions

Brain Metastases

Keywords

brain metastases; brain mets; WBRT

Outcome Measures

Primary Outcomes (2)

• Evaluate feasibility of utilizing a telephone assessment in patients with brain metastases

  The telephone-based tool will be considered feasible if the proportion of participants who complete baseline and follow-up telephone-based assessments is the same as or greater than the proportion of participants who complete the in-clinic assessments.

  1.5 years

• Evaluate the interprocedure (telephone vs. clinic) reliability

  Cronbach's alpha coefficient at each time point (baseline, 1 month, 4 months) will be calculated to assess the following z scores: Patient results from individual neurocognitive tests will be converted to a z score (the number of standard deviations above or below the mean). Overall averaged global z scores will be compared between the telephone and clinic assessments using the Toronto BNB. Cronbach's alpha coefficient will be evaluated as follows: 0-0.2 poor agreement; 0.3-0.4 fair agreement; 0.5-0.6 moderate agreement; 0.7-0.8 strong agreement; \>0.8 very strong agreement.

  1.5 years

Secondary Outcomes (2)

• Evaluate the change in neurocognitive function before and after WBRT using the Toronto BNB

  1.5 years

• Evaluate sensitivity to change (responsiveness) of the Toronto BNB (in clinic and by telephone)

  1.5 years

Study Arms (1)

QOL Assessment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with newly diagnosed brain metastases planned for whole brain radiotherapy

You may qualify if:

• Adult (\> 18 years old) with newly diagnosed brain metastases planned for whole brain radiotherapy
• Performance status ECOG 0-2
• English-speaking (due to small sample-size in this pilot study, only English testing will be completed)

You may not qualify if:

• Prior whole brain radiotherapy
• Presence of any condition which can prevent completion of neurocognitive assessment, including:
• Hearing impairment which is sufficient to prevent the patient from comprehending English instructions in a quiet environment
• Major psychiatric diagnosis or neurological condition associated with cognitive impairment which, in the judgement of the investigator, would make the patient inappropriate for study participation (e.g., schizophrenia, multiple sclerosis, Parkinson's disease, prior ischemic stroke, dementia, traumatic brain injury with loss of consciousness for greater than 30 minutes, expressive/receptive aphasia, developmental delay)
• Patients with planned systemic therapy or additional radiotherapy within the interval between clinic and telephone Toronto BNB testing
• Minimal English skills such that subjects would be unable to follow simple English instructions (either verbal or written) or be unable to read questionnaires of a grade 8 standard with the help of a research assistant.

Sponsors & Collaborators

• University Health Network, Toronto: lead

Study Sites (3)

Southlake Regional Health Centre

Newmarket, Ontario, L3Y2P9, Canada

Location

Sunnybrook Hospital - Odette Cancer Centre

Toronto, Ontario, M4N3M5, Canada

Location

Princess Margaret Cancer Centre

Toronto, Ontario, M5G2M9, Canada

Location

MeSH Terms

Conditions

Brain Neoplasms

Condition Hierarchy (Ancestors)

Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases

Study Officials

• Caroline Chung, MD

  University Health Network, Toronto

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 6, 2014
• First Posted: March 10, 2014
• Study Start: September 1, 2014
• Primary Completion: February 2, 2017
• Study Completion: February 2, 2017
• Last Updated: February 8, 2017

Record last verified: 2017-02

Locations

CA (3)